top of page
Search

Lexaria Bioscience prices $2 million public offering - proceeds to advance drug delivery technology


  • Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids, antiviral drugs, PDE5 inhibitors and more.

  • DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier.

Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today announced the pricing of its public offering of 2,106,000 units, with each unit consisting of one share of common stock (or one pre-funded warrant to purchase one share of common stock in lieu thereof), and one warrant to purchase one share of common stock. Each unit is being sold at a public offering price of $0.95. The warrants will be immediately exercisable at a price of $0.95 per share and will expire five years from the date of issuance. The shares of common stock (or pre-funded warrants in lieu thereof) and accompanying warrants can only be purchased together in this offering, but will be issued separately and will be immediately separable upon issuance. Gross proceeds, before deducting placement agent fees and other offering expenses, are expected to be approximately $2.0 million. The offering is expected to close on May 11, 2023, subject to customary closing conditions. Maxim Group LLC is acting as sole placement agent in connection with this offering. The securities described above are being offered pursuant to a registration statement on Form S-1, as amended (File No. 333-271096) (the "Registration Statement"), which was declared effective by the Securities and Exchange Commission (the "SEC") on May 8, 2023. The offering is being made only by means of a prospectus which is a part of the Registration Statement. A preliminary prospectus relating to the offering has been filed with the SEC. Copies of the final prospectus relating to this offering, when available, will be filed with the SEC and may be obtained from Maxim Group LLC, 300 Park Avenue, 16th Floor, New York, NY 10022, at (212) 895-3745. This press release shall not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. About Lexaria Bioscience Corp. Lexaria Bioscience Corp.’s patented drug delivery technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream through oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids, antiviral drugs, PDE5 inhibitors and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 30 patents granted and many patents pending worldwide.


For more information, please visit www.lexariabioscience.com.


Source: Lexaria Bioscience Corp.

_____________________________________________________ FC Global Strategies enables medical, pharma, healthcare, medical device and healthcare IT companies to achieve their business and financial goals


Since 1979 FC Global Strategies has enabled companies globally to achieve their business and financial objectives. If your company has business or financial objectives check out: Strategic advisory services provided by FC Global Strategies




Medical and Pharma Insider’s AI Connect Marketing Program


Click here to schedule a complimentary call to discuss your company's business and financial goals.


Medical and Pharma Insider is a program of FC Global Strategies.


FC Global Strategies' Contacts


North America and Latin America

Jeffrey Friedland, +1 646 450 8909


The Middle East, North Africa and Eastern Europe

David Krutonog, +972 50 974 3429


Southeast Asia, Asia-Pacific, Australia, and New Zealand

Ross Swan, +65 9181 9472



تعليقات


تم إيقاف التعليق.
bottom of page